AMRA Presenting
at EASD 2026
Insights Within
Advanced Muscle Composition and Fat Distribution Imaging
AMRA Medical is pleased to be participating in the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, where leading researchers, clinicians, and industry experts will come together to discuss the latest advances in diabetes, obesity, and metabolic health.
As obesity treatment continues to evolve, understanding what happens to muscle and fat during weight loss is becoming increasingly important. AMRA’s quantitative MRI analysis technology enables researchers to look beyond body weight, BMI, and lean mass alone by providing standardized insight into muscle composition, muscle volume, and fat distribution.
At EASD 2026, AMRA’s Chief Scientific Officer Dr. Jennifer Linge will contribute to the symposium “Preserving muscle during GLP-1 RA treatment: insights from the trevogrumab COURAGE study,” highlighting the role MRI-based analyses play in building a more detailed understanding of muscle during obesity treatment.

Spotlight: AMRA Symposium Presentation
COURAGE Body Composition:
Muscle Composition Assessed by MRI

Thursday, October 1
17:59 – 18:12 CEST
Dr. Jennifer Linge
Chief Scientific Officer, AMRA Medical
The symposium, “Preserving muscle during GLP-1 RA treatment: insights from the trevogrumab COURAGE study,” will run from 17:30–18:30 CEST in Vienna Hall. This session will bring together experts in obesity and diabetes research to examine body composition during treatment and explore why understanding muscle is becoming increasingly relevant as the obesity treatment landscape evolves.
Connect with AMRA at EASD 2026
Discover how AMRA’s quantitative MRI solutions provide deeper insights into muscle composition and fat distribution to support obesity and metabolic research.
Attending EASD? Schedule a meeting with our team or contact info@amramedical.com to learn more.